{"entity":{"id":"nct05526755","kind":"trial","name":"A Study of 5 Years of Adjuvant Osimertinib in Completely Resected Epidermal Growth Factor Receptor Mutation (EGFRm) Non-small Cell Lung Carcinoma (NSCLC)","aka":[],"tldr":"A phase 2 trial of Osimertinib in non-small-cell lung cancer, run by AstraZeneca, active and no longer recruiting.","summary":"A Study of 5 Years of Adjuvant Osimertinib in Completely Resected Epidermal Growth Factor Receptor Mutation (EGFRm) Non-small Cell Lung Carcinoma (NSCLC) is a phase 2 interventional study registered as NCT05526755 by AstraZeneca, with 188 participants enrolled, started 2023-03-06 and due to reach its primary completion in 2029-11-22. Interventions recorded: Osimertinib 80 mg/40 mg.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05526755","url":"https://clinicaltrials.gov/study/NCT05526755"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":["osimertinib"],"companies":["astrazeneca"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05526755","phase":"2","setting":"An Open-label, Single-arm, Phase II, Multinational, Multicentre Study to Assess the Efficacy and Safety of 5 Years of Osimertinib in Participants With EGFRm-positive Stage II-IIIB NSCLC, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy","sponsor":"AstraZeneca","enrolled":188,"outcomes":[]},"route":"/trials/nct05526755/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"drug":[{"id":"osimertinib","kind":"drug","name":"Osimertinib","route":"/drugs/osimertinib/"}],"company":[{"id":"astrazeneca","kind":"company","name":"AstraZeneca","route":"/companies/astrazeneca/"}]}}